HZN-1116

DRUG2 trials

Sponsors

Horizon Therapeutics Ireland Designated Activity Company, Amgen

Conditions

Sjogren's SyndromeSjögren’s Syndrome

Phase 2

A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

TerminatedNCT06312020

AmgenSjogren's Syndrome

Start: 2024-05-09End: 2026-04-28Updated: 2026-05-08

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome.

Active, not recruitingCTIS2023-507680-19-00

Horizon Therapeutics Ireland Designated Activity CompanySjögren’s Syndrome

Start: 2024-11-28Target: 151Updated: 2025-07-28